# Ophthalmology (retina) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jackie Robinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML037-SYN-TD
- Date: 1971-07-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Priya Ostrowski-Lane, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Marcus Delacroix-Hale, MD

## Reason for consultation

Blurred vision in both eyes for two months and new floaters in the right eye for four days in a 52-year-old man with type 2 diabetes for about fifteen years and an A1c of 10.4%. Snellen acuity 20/200 right and 20/80 left; the undilated view of the right fundus is poor. Please examine for proliferative retinopathy, vitreous hemorrhage, retinal detachment and macular edema, and treat as needed. **S**

## History

Mr. Robinson, 52, is seen at the request of Dr. Delacroix-Hale two days after he reported two months of blurred vision in both eyes and new floaters in the right eye. He has had no flashes, no curtain over his vision and no eye pain. He has had diabetes for about fifteen years, with high blood pressure, peripheral artery disease and two mild strokes a year ago, and his last dilated eye examination was more than two years ago. He takes aspirin. He is grieving the recent death of his son and is frightened of losing his sight. He agreed to examination with dilating drops, ultrasound and OCT, and, after the risks of infection, raised eye pressure and bleeding were explained, to injections today. **S**

## Examination

| System | Finding |
|---|---|
| Visual acuity | Best-corrected 35 letters right and 56 letters left |
| Anterior segment | Clear corneas; mild early lens opacity in both eyes; no new vessels on the iris or in the angle on gonioscopy |
| Right fundus (dilated) | Dense inferior vitreous hemorrhage; neovascularization of the disc seen superiorly; macular thickening with exudates where visible |
| Left fundus (dilated) | Neovascularization of the disc and elsewhere; intraretinal hemorrhages in four quadrants; hard exudates and thickening at the center of the macula |
| Vital signs | Blood pressure 148/90 and pulse 82, measured today |

BP 148/90 mmHg; pulse 82 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 103.8 kg; BMI 32 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Delacroix-Hale's note and results: A1c 10.4%; blood pressure 152/92; eGFR 79; urine albumin-to-creatinine ratio 86 mg/g; LDL 142 mg/dL. Today: best-corrected acuity 35 letters right and 56 letters left (about 20/200 and 20/80). Intraocular pressure 16 mmHg right and 15 left. OCT: center-involving macular edema, central subfield 412 microns right and 468 left, with intraretinal fluid in both eyes. B-scan ultrasound of the right eye: vitreous hemorrhage, retina attached, no tractional detachment. Best-corrected visual acuity, right eye (ETDRS letters): 35 (low); Best-corrected visual acuity, left eye (ETDRS letters): 56 (low); Central subfield thickness by OCT, right eye: 412 um (high); Central subfield thickness by OCT, left eye: 468 um (high). All results are synthetic.

## Assessment

1. **Proliferative diabetic retinopathy with center-involving diabetic macular edema, both eyes** (E11.3513). High-risk proliferative retinopathy in both eyes with center-involving macular edema and reduced vision in both. Anti-VEGF injections treat both the edema and the new vessels and are the first treatment; panretinal photocoagulation adds durable control of the proliferative disease and lessens the burden of frequent injections, and is done when the view allows. **S**
2. **Vitreous hemorrhage, right eye** (H43.11). From the new vessels; the retina is attached and there is no traction, so vitrectomy is not needed now. Most such hemorrhages clear over weeks with anti-VEGF treatment. **S**
3. **Type 2 diabetes** (E11.65). Better glucose control will protect his eyes over years, but a very rapid fall in A1c can worsen proliferative retinopathy for a time, and semaglutide was associated with more retinopathy complications in a cardiovascular outcomes trial, mainly in people with existing retinopathy and large early A1c falls. A steady fall of about one point every three months is reasonable, and a GLP-1 receptor agonist can be started once the proliferative disease is controlled, with monthly retina review. An SGLT2 inhibitor raises no retinal concern. **S**

## Recommendations

1. Aflibercept 2 mg in both eyes today and monthly for three doses, then treat-and-extend by OCT and examination.
2. Panretinal photocoagulation to the right eye once the hemorrhage clears enough to allow it, and to the left eye if new vessels persist after the first injections.
3. Vitrectomy if the right hemorrhage does not clear within one to three months, or if a retinal detachment develops.
4. Continue aspirin 81 mg: it does not increase the risk or severity of vitreous hemorrhage in diabetic retinopathy, and he needs it after his strokes.
5. Lower the A1c gradually, about one point every three months; delay a GLP-1 receptor agonist until I judge the retina stable, then start at the lowest dose with monthly retina review; an SGLT2 inhibitor and blood pressure and lipid treatment can go ahead now.
6. Low-vision evaluation now (magnifiers, lighting, phone and computer voice tools), a talking glucose meter and an insulin pen with audible clicks; he should not drive until acuity is reassessed.
7. Return the same day for a curtain over the vision, a sudden fall in vision, flashes, or a painful red eye after an injection.

## Strengths and supports

- Strengths: discipline, a long habit of facing pressure in public, his faith, his work for civil rights, and a household that supports him **S**

## Communication

Discussed with Dr. Delacroix-Hale by phone the same day. Mr. Robinson was shown his OCT images and told what the injections and laser can and cannot do; he asked many questions and chose to begin today. **S**

## Follow-up

Retina clinic in four weeks for the second injections, then monthly while treating. I will advise Dr. Delacroix-Hale when the retina is stable enough to start a GLP-1 receptor agonist. **S**

## Guideline basis

- 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- Diabetic Retinopathy Preferred Practice Pattern (2025), American Academy of Ophthalmology (Ophthalmology 2025; Lim JI, et al.)
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) (2016), New England Journal of Medicine (Marso SP, et al.)
- 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (2021), American Heart Association and American Stroke Association (Stroke 2021)
